Compare FN & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | RVMD |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | 883 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7B | 19.2B |
| IPO Year | 2007 | N/A |
| Metric | FN | RVMD |
|---|---|---|
| Price | $662.58 | $155.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $489.14 | $135.05 |
| AVG Volume (30 Days) | 676.2K | ★ 2.8M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.21 | N/A |
| EPS | ★ 5.77 | N/A |
| Revenue | ★ $3,419,327,000.00 | N/A |
| Revenue This Year | $36.87 | N/A |
| Revenue Next Year | $18.16 | $411.49 |
| P/E Ratio | $119.16 | ★ N/A |
| Revenue Growth | ★ 18.60 | N/A |
| 52 Week Low | $167.33 | $34.00 |
| 52 Week High | $708.20 | $155.01 |
| Indicator | FN | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.63 | 88.14 |
| Support Level | $429.50 | $93.39 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 38.52 | 4.77 |
| MACD | 12.34 | 7.00 |
| Stochastic Oscillator | 79.82 | 99.13 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.